Unlocking the Therapeutic Potential of Neuroplastogens

A Biotech Platform Company


The next big opportunity is the development of non-hallucinogenic serotonin 5-HT2A receptor agonists as therapeutics for both psychiatric and non-psychiatric indications.

Neuroplastogens are an emerging class of compounds that harness the mechanisms of psychedelics but are non-hallucinogenic and bypass the need for in-clinic administration, offering improved tolerability and scalability.

Compelling preclinical evidence of enhanced neuroplasticity and cellular resilience support their potential to provide significant clinical benefit in a wide range of disease areas, from psychiatry to ophthalmology.

neuroplastogen photoneuroplastogen photoneuroplastogen photo
neuroplastogen photo

Negev labs

A Biotech Platform Company


Unlock the full therapeutic potential of neuroplastogens


Negev Labs identifies and develops the most promising neuroplastogen therapeutics

Source and Validate

Identify the most promising drug candidates via expert due diligence

Transform to Clinical-Ready

Guide early discoveries through validation to clinical proof-of-concept

Partner or Spin-out for Impact

Maximize potential through licensing or stand-alone venture spin-out

Phase 1b

Our lead candidate starts clinical

trials in Q3 2024 in patients


more projects

in pre-clinical development
and in discovery

Management Team

Ken Belotsky portrait

Ken Belotsky

CEO, Co-Founder

Partner at Negev Capital since 2021.
15 years managing startups. Co-founder of Bright Box acquired by Zurich Insurance in 2018. Co-founder of BrightConsult acquired by Incadea (Cox Automotive) in 2011.

Kostia Adamsky portrait

Kostia Adamsky

COO, Co-Founder

Principal at Negev Capital since 2022
. VP Ops & Tech at Levco Pharmaceuticals Ltd. CEO & VP Ops at Regenera Pharma LTD.
 Director and co-CEO at Targia Pharmaceuticals. PhD in cell biology.

Heresh Rezavandi portrait

Heresh Rezavandi

Chief Strategy & Partnering Officer

14+ experience in life science R&D, portfolio, search and evaluation, BD&L, marketing, strategy in global roles at UCB, Bayer, Roche and Angelini​. PhD in Biochemistry.

Shlomi Raz portrait

Shlomi Raz


Founder & CEO of Eleusis Therapeutics and President & CBO of Beckley Psytech. MD at Goldman Sachs & JPMorgan. MA in psychology from NYU and a BS in finance from Georgetown University.

Vadim Uzberg portrait

Vadim Uzberg

Board Dir., Co-Founder Corp Dev.

Partner at Negev Capital. Private Equity professional, since 1999. Partner at Baring Capital Partners.

Contact us

Thank you for getting in touch!

We appreciate you contacting us. One of our colleagues will get back in touch with you soon!

Have a great day!

Oops! Something went wrong while submitting the form.